Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older;~2. HSV-2 seropositive by Western Blot;~3. not receiving any drugs with known anti-HSV-2 activity for study duration;~4. history of primary genital herpes infection within past 6 months OR history of 4 or more HSV recurrences per year during the past year OR 4 or more recurrences per year prior to initiation of suppressive antiviral therapy;~5. able to comply with the study protocol;~6. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~7. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~8. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~9. planning to remain resident in the area of the study center for the duration of the study participation;~10. HIV seronegative.~Exclusion Criteria:~1. hypersensitivity to acyclovir or valacyclovir;~2. pregnant women;~3. HIV positive or other immunosuppressed state, including chronic steroid use. Intermittent nasal or topical steroids are acceptable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose (Type: ACTIVE_COMPARATOR): None
- High-dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).